Skip to main content

Table 1 Patient demographics and treatment characteristics (n = 40). Mann-Whitney U test was used for continuous variables and Chi-Square test was used for categorical variables

From: Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: a lesion-based and patient-based analysis

 

All CMR

Sustained CMR

PMD

P value

Median Age (years)

60 (35–80)

62 (35–74)

59 (41–80)

0.408

Sex (Male:Female)

24:16

5:9

19:7

0.021

ECOG status

    

• 0

3

3

0

 

• 1

35

11

24

0.013

• 2

2

0

2

 

Primary site

    

• Right colon

9

5

4

0.149

• Left colon

31

9

22

 

T staging

    

• T3

16

7

9

0.266

• T4

18

6

12

 

• Tx

6

1

5

 

N staging

    

• N0

2

1

1

 

• N1

15

6

9

0.432

• N2

18

6

12

 

• Nx

5

1

4

 

KRAS status

    

• Wild type

29

11

18

0.355

• Mutation

8

1

7

 

• Unknown

3

2

1

 

Metastatic Site

    

• Liver

17

3

14

0.049

• Lung

7

3

4

0.416

• Lymph node

20

8

12

0.520

• Peritoneal

11

4

7

0.914

• Others

4

2

2

0.520

Chemotherapy regime

    

• XELOX

29

9

20

 

• FOLFOX

5

3

2

 

• XELIRI

2

1

1

0.989

• FOLFIRI

2

1

1

 

• XELODA

2

0

2

 

Biological agent

    

• None

16

9

7

 

• Bevacizumab

8

1

7

0.021

• Cetuximab

16

4

12

 

• Median number of chemotherapy cycle to achieve complete metabolic response (CMR)

4 (3–12)

5 (4–12)

4 (3–10)

0.234

• Median number of chemotherapy cycles received after CMR was achieved

3 (0–8)

3 (0–8)

3 (0–8)

0.980